AlOmeir Othman Khalid
Department of Pharmacy Practice, College of Pharmacy, Aldawadmi, Shaqra University, Shaqra, Saudi Arabia.
J Pharm Bioallied Sci. 2023 Jan-Mar;15(1):21-28. doi: 10.4103/jpbs.jpbs_625_22. Epub 2023 Apr 14.
Both clinical and experimental findings demonstrated a rise in prostate cancer in chronic renal illness. However, the clinical data associated with CKD was not looked at the context of prostate cancer. The study aims to investigate prostate cancer risk in CKD patients using clinical data via systemic review and meta-analysis.
Using pertinent pairing keywords, I carried out a thorough exploration of PubMed/MEDLINE and Web of Science. The pooled HR with 95% CI of the considered clinical findings was estimated involving the general inverse variance outcome type. With RevMan 5.3, the total pooled estimate meta-analysis was evaluated utilizing the random effects model.
Total of six findings were considered for this analysis, with a total of 2,430,246 participants. The age and mean follow-up of the included patients and studies ranged from 55 to 67.4 years and 10.1 to 12 years, respectively. The meta-analysis showed no significant risk of prostate cancer among CKD patients (HR: 0.92; 95% CI: 0.60-1.41 = 0.70). The results from subgroup analysis based on eGFR levels ranged ≥30-59 ml/min per 1.73 m and also found no significant risk of prostate cancer among CKD patients (HR: 1.04; 95% CI: 0.92-1.18; = 0.52). Here I did not report statistical heterogeneity found (Q = 0.56, I = 0%, = 0.87). As per the Newcastle-Ottawa scale, the included studies suggested good quality.
The results suggest no significant risk of developing prostate cancer among CKD patients. Therefore, well-designed prospective cohort studies with stages of CKD and clear predefined prior history and causative factors are needed to support the present evidence strongly.
临床和实验结果均表明,慢性肾病患者的前列腺癌发病率有所上升。然而,与慢性肾脏病(CKD)相关的临床数据并未在前列腺癌的背景下进行研究。本研究旨在通过系统评价和荟萃分析,利用临床数据调查CKD患者患前列腺癌的风险。
使用相关配对关键词,我对PubMed/MEDLINE和科学网进行了全面检索。采用一般逆方差结果类型估计所考虑临床研究结果的合并风险比(HR)及95%置信区间(CI)。使用RevMan 5.3软件,采用随机效应模型对总合并估计值进行荟萃分析。
本分析共纳入6项研究结果,参与者总数为2430246人。纳入患者和研究的年龄及平均随访时间分别为55至67.4岁和10.1至12年。荟萃分析显示,CKD患者患前列腺癌的风险无显著增加(HR:0.92;95%CI:0.60 - 1.41;P = 0.70)。基于估算肾小球滤过率(eGFR)水平≥30 - 59 ml/min/1.73 m²的亚组分析结果也显示,CKD患者患前列腺癌的风险无显著增加(HR:1.04;95%CI:0.92 - 1.18;P = 0.52)。此处未报告发现的统计异质性(Q = 0.56,I² = 0%,P = 0.87)。根据纽卡斯尔 - 渥太华量表,纳入研究质量良好。
结果表明,CKD患者患前列腺癌的风险无显著增加。因此,需要设计良好的前瞻性队列研究,明确CKD分期以及预先定义明确的病史和致病因素,以有力支持现有证据。